Business
Telo Genomics Achieves Noteworthy International Standards Organization ("ISO") Regulatory Accreditation
Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - Telo Genomics Corp.  (TSXV: TELO)...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Achieves Noteworthy International Standards Organization (\"ISO\") Regulatory AccreditationToronto, Ontario--(Newsfile Corp. - September 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") is proud to announce that it has successfully completed the final assessment and achieved ISO 15189 accreditation. ISO 15189 is the international standard specific for clinical laboratories. The ISO 15189 accreditation qualifies Telo to offer its TeloView tests as laboratory developed tests (LDTs) for clinical use from its central laboratory in Toronto.In achieving the ISO 15189 accreditation, Telo underwent a rigorous assessment that was conducted by Accreditation Canada Diagnostics. The assessment covered Telo's quality management system (QMS), laboratory information system (LIS), technical competence, and proficiency in conducting high value molecular diagnostics tests. Telo achieved over 90% compliance in the conducted assessment.\"Completing ISO 15189 accreditation is a significant accomplishment for Telo Genomics as it demonstrates our excellence in providing high quality clinical laboratory services according to international standards,\" said Sherif Louis, Telo's President and CTO. \"Our ISO 15189 accreditation also aligns with the planned launch of the TeloView-SMM physician experience program \"SMART\" as Telo's first clinical offering later this year.\"About TeloView-SMMTeloView-SMM has the potential to be an important tool for physicians managing the care of patients diagnosed with Smoldering Multiple Myeloma. The proprietary assay (and associated platform technology) quantifies individual patients' risk of transformation/progression by measuring the 3D structure and spatial organization of telomeres. This molecular signature identifies high-risk SMM patients who are likely to benefit from earlier treatment intervention. The larger subset of low-risk patients may not require immediate treatment and can be regularly monitored using the TeloView-SMM assay along with standard phenotypic measures. Over 200,000 patients in the United States are currently living with smoldering Multiple Myeloma. The TeloView-SMM assay has a potential total addressable market of over 500,000 tests per year.About Telo Genomics Telo Genomics Corp. is a biotech company pioneering the most comprehen...